Information  X 
Enter a valid email address

EPIC/TIDM matching '0VF9'

Date
Time Source
Company
Announcement
18 Apr 2019 1:00 pm GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
07 Aug 2018 12:00 pm GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone
31 Jul 2018 10:00 pm GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix Intends to Pursue U.S. Listing
14 Jun 2018 8:25 pm GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
07 Jun 2018 12:00 pm GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the "Shock and Kill" Approach
25 May 2018 6:45 am GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
19 Mar 2018 11:00 am GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
08 Jan 2018 2:09 pm GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement
12 Dec 2017 12:30 pm GNW   Factsheet Resverlogix Corp (0VF9) Nature's Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
04 Dec 2017 12:00 pm GNW   Factsheet Resverlogix Corp (0VF9) Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t